CN102123732A - 用于引发免疫应答的组合物，方法及试剂盒 - Google Patents

用于引发免疫应答的组合物，方法及试剂盒 Download PDF

Info

Publication number
CN102123732A
CN102123732A CN2009801288723A CN200980128872A CN102123732A CN 102123732 A CN102123732 A CN 102123732A CN 2009801288723 A CN2009801288723 A CN 2009801288723A CN 200980128872 A CN200980128872 A CN 200980128872A CN 102123732 A CN102123732 A CN 102123732A
Authority
CN
China
Prior art keywords
cell
cmv
antigen
dna
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801288723A
Other languages
English (en)
Chinese (zh)
Inventor
J·H·桑普森
D·A·米切尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University filed Critical Duke University
Publication of CN102123732A publication Critical patent/CN102123732A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/812—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/47—Brain; Nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
CN2009801288723A 2008-06-20 2009-06-19 用于引发免疫应答的组合物，方法及试剂盒 Pending CN102123732A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7458208P 2008-06-20 2008-06-20
US61/074,582 2008-06-20
PCT/US2009/047987 WO2009155535A2 (en) 2008-06-20 2009-06-19 Compositions, methods and kits for eliciting an immune response

Publications (1)

Publication Number Publication Date
CN102123732A true CN102123732A (zh) 2011-07-13

Family

ID=41434717

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801288723A Pending CN102123732A (zh) 2008-06-20 2009-06-19 用于引发免疫应答的组合物，方法及试剂盒

Country Status (8)

Country Link
US (12) US8425898B2 (enExample)
EP (4) EP4218806A1 (enExample)
JP (3) JP2011525191A (enExample)
CN (1) CN102123732A (enExample)
AU (1) AU2009259923B2 (enExample)
CA (1) CA2728739C (enExample)
DK (1) DK3156069T3 (enExample)
WO (1) WO2009155535A2 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019151759A1 (ko) * 2018-02-02 2019-08-08 주식회사 에스엘백시젠 신규 백신 면역보조제
CN111315404A (zh) * 2017-11-06 2020-06-19 美利坚合众国, 由健康及人类服务部部长代表 利用预先存在的微生物免疫的癌症治疗
CN117169518A (zh) * 2023-11-03 2023-12-05 赛德特(北京)生物工程有限公司 T淋巴细胞制剂中的cd3抗体残留物的检测方法和试剂盒
CN117257925A (zh) * 2023-09-20 2023-12-22 青岛大学 基于人巨细胞病毒编码即刻早期蛋白ie的疫苗、其制备方法和应用

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2155782A2 (en) 2007-03-26 2010-02-24 Dako Denmark A/S Mhc peptide complexes and uses thereof in infectious diseases
WO2009003493A2 (en) 2007-07-03 2009-01-08 Dako Denmark A/S Mhc multimers, methods for their generation, labeling and use
WO2009039854A2 (en) 2007-09-27 2009-04-02 Dako Denmark A/S Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics
DK2254592T3 (da) 2008-02-28 2019-09-09 Dako Denmark As MHC-multimerer til Borrelia-diagnostik og sygdom
CA2728739C (en) * 2008-06-20 2017-07-11 Duke University Use of human cytomegalovirus antigens to enhance immune responses to cancer cells
WO2010009735A2 (en) 2008-07-23 2010-01-28 Dako Denmark A/S Combinatorial analysis and repair
GB0817244D0 (en) 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
WO2010037402A1 (en) 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
EP3238782A3 (en) * 2010-04-06 2018-01-03 ExoCyte Therapeutics Pte, LTD Methods of treating cancer
EP2697248B1 (en) * 2011-04-15 2020-03-11 Nauclér, Cecilia Genetic variant of cytomegalovirus (cmv)
CN102363818B (zh) * 2011-06-28 2013-01-02 同昕生物技术（北京）有限公司 同时检测人ebv、bkv和 cmv的三重实时荧光定量pcr方法及试剂盒
EP3269388A1 (en) * 2012-10-30 2018-01-17 Pfizer Inc. Recombinant particle based vaccines against human cytomegalovirus infection
US10106817B2 (en) * 2013-02-14 2018-10-23 The J. David Gladstone Institutes Compositions and methods of use thereof for identifying anti-viral agents
EP3888675A1 (en) * 2013-09-24 2021-10-06 Duke University Compositions, methods and kits for eliciting an immune response
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
WO2015073801A1 (en) 2013-11-14 2015-05-21 Duke University Tetanus toxoid and ccl3 improve dc vaccines
EP3074770B1 (en) 2013-11-26 2020-04-29 Duke University Immune monitoring to predict and prevent infection
EP3215165B1 (en) 2014-11-05 2020-12-23 Memorial Sloan Kettering Cancer Center Methods of selecting t cell line and donor thereof for adoptive cellular therapy
WO2016146143A1 (en) 2015-03-16 2016-09-22 Amal Therapeutics Sa Cell penetrating peptides and complexes comprising the same
US10746736B2 (en) * 2015-03-26 2020-08-18 University Of Houston System Integrated functional and molecular profiling of cells
HK1254397A1 (zh) 2015-06-26 2019-07-19 纪念斯隆-凯特林癌症中心 通过t细胞疗法治疗cmv视网膜炎的方法
EP3364981A4 (en) 2015-10-22 2019-08-07 ModernaTX, Inc. VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS
EP3364949A4 (en) 2015-10-22 2019-07-31 ModernaTX, Inc. CANCER VACCINES
WO2017096247A1 (en) * 2015-12-04 2017-06-08 Mayo Foundation For Medical Education And Research Methods and vaccines for inducing immune responses to multiple different mhc molecules
JP7653759B2 (ja) 2016-01-20 2025-03-31 フェイト セラピューティクス，インコーポレイテッド 養子免疫療法における免疫細胞調節のための組成物および方法
AU2017210031C1 (en) 2016-01-20 2020-11-26 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
EP3429618B1 (en) 2016-03-16 2024-02-21 Amal Therapeutics SA Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist for use in medicine
KR20190057345A (ko) 2016-09-21 2019-05-28 아말 테라퓨틱스 에스에이 암 치료를 위한, 세포 투과 펩타이드, 멀티 에피토프 및 tlr 펩타이드 작용제를 포함하는 융합체
CA3037002A1 (en) 2016-09-23 2018-03-29 Memorial Sloan Kettering Cancer Center Generation and use in adoptive immunotherapy of stem cell-like memory t cells
EP3528821A4 (en) 2016-10-21 2020-07-01 ModernaTX, Inc. HUMAN CYTOMEGALOVIRUS VACCINE
US11932870B2 (en) 2016-12-05 2024-03-19 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
CA3064375A1 (en) 2017-05-25 2018-11-29 Memorial Sloan Kettering Cancer Center Use of the il-15/il-15ra complex in the generation of antigen-specific t cells for adoptive immunotherapy
EP3700553A1 (en) 2017-10-23 2020-09-02 Atara Biotherapeutics, Inc. Methods of managing tumor flare in adoptive immunotherapy
WO2020127222A2 (en) 2018-12-17 2020-06-25 Immudex Aps Panel comprising borrelia mhc multimers
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
KR20220038608A (ko) * 2019-05-31 2022-03-29 배리에이션 바이오테크놀로지스 아이엔씨. 다형성 교모세포종의 치료를 위한 면역치료 조성물
CN114466659A (zh) * 2019-09-09 2022-05-10 葛兰素史克生物有限公司 免疫治疗组合物
JP2023078487A (ja) * 2020-04-08 2023-06-07 アステラス製薬株式会社 がんの処置に用いるｐｐ６５含有人工アジュバントベクター細胞
ES2987329T3 (es) 2020-05-22 2024-11-14 Philogen Spa Terapia con el inmunoconjugado de TNF-a para el tratamiento de tumores cerebrales
TWI871709B (zh) 2020-06-21 2025-02-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽
US20230293673A1 (en) * 2020-08-06 2023-09-21 La Jolla Institute For Immunology Methods for treating and preventing cytomegalovirus infection
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
GB2603166A (en) * 2021-01-29 2022-08-03 Thelper As Therapeutic and Diagnostic Agents and Uses Thereof
US20240226159A9 (en) * 2021-03-09 2024-07-11 Board Of Regents, The University Of Texas System Low intensity ultrasound combination cancer therapies

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030118602A1 (en) * 1996-11-12 2003-06-26 Diamond Don J. HCMV-reactive T cells and uses therefor

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
US6207161B1 (en) 1986-07-16 2001-03-27 City Of Hope Induction of cytolytic T-lymphocytes with cytomegalovirus polypeptides
US4906564A (en) 1987-03-13 1990-03-06 The United States Of America As Represented By The Secretary Of The Army Antigenic determinants recognized by antibodies obtained using a pathogenic agent or a derivative thereof that presents a restricted set of antigens
AU658836B2 (en) 1990-09-25 1995-05-04 Xenova Research Limited Viral defective vaccine produced by transcomplementing cell line
AU695584B2 (en) * 1993-01-28 1998-08-20 Novartis Pharmaceutical Corporation Human monoclonal antibodies to cytomegalovirus
EP0689603A1 (en) 1993-03-19 1996-01-03 Cantab Pharmaceuticals Research Limited Defective mutant non-retroviral virus (e.g. hsv) as vaccine
US6448389B1 (en) * 1996-04-23 2002-09-10 The Wistar Institute Of Anatomy And Biology Human cytomegalovirus DNA constructs and uses therefor
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
US6074645A (en) * 1996-11-12 2000-06-13 City Of Hope Immuno-reactive peptide CTL epitopes of human cytomegalovirus
US6156317A (en) * 1996-11-12 2000-12-05 City Of Hope Immuno-reactive peptide CTL epitopes of human cytomegalovirus
US6503503B1 (en) 1997-05-13 2003-01-07 Duke University Allogeneic cellular vaccine
US6013258A (en) 1997-10-09 2000-01-11 Zycos Inc. Immunogenic peptides from the HPV E7 protein
US6291446B1 (en) 1998-03-05 2001-09-18 Eli Lilly And Company Therapeutic treatment for cytomegalovirus infection
IL125608A0 (en) 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
AU771946B2 (en) 1998-08-31 2004-04-08 Oregon Health And Science University Prevention of cell migration initiation with CMV US28 receptor antagonists
US6572856B1 (en) 1998-09-10 2003-06-03 The University Of Virginia Patent Foundation Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies
US6350451B1 (en) 1999-06-25 2002-02-26 The Board Of Trustees Of The University Of Arkansas Immunotherapy of epithelial tumors using intralesional injection of antigens that induce a delayed type hypersensitivity reaction
US7005131B1 (en) 1999-08-13 2006-02-28 The Rockefeller University Protective antigen of Epstein Barr Virus
AU2001240109A1 (en) 2000-03-07 2001-09-17 U.S. Army Medical Research Institute Of Infectious Diseases Dna vaccines against poxviruses
JP2003527847A (ja) 2000-03-21 2003-09-24 ジェンザイム・コーポレーション 治療用抗サイトメガロウイルス化合物
EP1146119A1 (en) * 2000-04-12 2001-10-17 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method for obtaining specific T-lymphocytes, and for identifying unknown epitopes
US7025968B2 (en) * 2000-08-30 2006-04-11 Chemocentryx, Inc. CMV vaccines
US20040241140A1 (en) 2000-11-01 2004-12-02 Pavlakis George N. Expression vectors able to elicit improved immune response and methods of using same
CA2437201C (en) 2001-02-02 2008-11-18 Chemocentryx, Inc. Methods and compositions useful for stimulating an immune response
AUPR395801A0 (en) 2001-03-26 2001-04-26 Austin Research Institute, The Antibodies against cancer
AUPR593101A0 (en) * 2001-06-26 2001-07-19 Council Of The Queensland Institute Of Medical Research, The Cytomegalovirus t cell epitopes
WO2004023091A2 (en) 2002-09-03 2004-03-18 The Uab Research Foundation Localization of human cytomegalovirus nucleic acids and proteins in human cancer cells
US7740871B2 (en) 2002-09-19 2010-06-22 Johns Hopkins University School Of Medicine Cancer immunotherapy with a viral antigen-defined, immunomodulator-secreting cell vaccine
EP1408106B1 (en) 2002-10-11 2007-02-14 Sentoclone Therapeutics AB Cancer immuno-therapy
WO2004053095A2 (en) 2002-12-10 2004-06-24 Merix Bioscience, Inc. In situ maturation of dendritic cells
WO2004058166A2 (en) * 2002-12-23 2004-07-15 Vical Incorporated Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection
US7163685B2 (en) 2003-04-16 2007-01-16 City Of Hope Human cytomegalovirus antigens expressed in MVA and methods of use
US20050232933A1 (en) * 2003-09-30 2005-10-20 Zaia John A CMV-IE1 peptides and method of use
WO2006056027A1 (en) * 2004-11-29 2006-06-01 The Council Of The Queensland Institute Of Medical Research Human cytomegalovirus immunotherapy
WO2007130470A2 (en) * 2006-05-01 2007-11-15 The Regents Of The University Of California Cytomegalovirus peptides and methods of use thereof
WO2008039969A2 (en) 2006-09-28 2008-04-03 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
US8435510B2 (en) * 2007-08-08 2013-05-07 Sutter West Bay Hospitals Platelet derived growth factor receptor supports cytomegalovirus infectivity
CA2728739C (en) * 2008-06-20 2017-07-11 Duke University Use of human cytomegalovirus antigens to enhance immune responses to cancer cells
CN102076354A (zh) 2008-07-03 2011-05-25 杜克大学 用于引发免疫应答的组合物和方法
WO2015073801A1 (en) * 2013-11-14 2015-05-21 Duke University Tetanus toxoid and ccl3 improve dc vaccines

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030118602A1 (en) * 1996-11-12 2003-06-26 Diamond Don J. HCMV-reactive T cells and uses therefor

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111315404A (zh) * 2017-11-06 2020-06-19 美利坚合众国, 由健康及人类服务部部长代表 利用预先存在的微生物免疫的癌症治疗
WO2019151759A1 (ko) * 2018-02-02 2019-08-08 주식회사 에스엘백시젠 신규 백신 면역보조제
US11844834B2 (en) 2018-02-02 2023-12-19 Sl Vaxigen, Inc. Vaccine adjuvant
CN117257925A (zh) * 2023-09-20 2023-12-22 青岛大学 基于人巨细胞病毒编码即刻早期蛋白ie的疫苗、其制备方法和应用
CN117257925B (zh) * 2023-09-20 2024-05-28 青岛大学 基于人巨细胞病毒编码即刻早期蛋白ie的疫苗、其制备方法和应用
WO2025060134A1 (zh) * 2023-09-20 2025-03-27 青岛大学 基于人巨细胞病毒编码即刻早期蛋白ie的疫苗、其制备方法和应用
CN117169518A (zh) * 2023-11-03 2023-12-05 赛德特(北京)生物工程有限公司 T淋巴细胞制剂中的cd3抗体残留物的检测方法和试剂盒
CN117169518B (zh) * 2023-11-03 2024-01-19 赛德特(北京)生物工程有限公司 T淋巴细胞制剂中的cd3抗体残留物的检测方法和试剂盒

Also Published As

Publication number Publication date
JP2015134767A (ja) 2015-07-27
US20220378906A1 (en) 2022-12-01
EP3156069B8 (en) 2020-10-21
US20150335732A1 (en) 2015-11-26
EP3156069A1 (en) 2017-04-19
EP2303319A2 (en) 2011-04-06
US20130189224A1 (en) 2013-07-25
US11389530B2 (en) 2022-07-19
US9011835B2 (en) 2015-04-21
EP3766517A1 (en) 2021-01-20
US8425898B2 (en) 2013-04-23
US10632190B2 (en) 2020-04-28
EP3766517B1 (en) 2022-11-02
US20220401552A1 (en) 2022-12-22
EP3156069B1 (en) 2020-08-05
WO2009155535A2 (en) 2009-12-23
US20220370602A1 (en) 2022-11-24
CA2728739A1 (en) 2009-12-23
US11376322B2 (en) 2022-07-05
EP2303319A4 (en) 2012-09-26
US20200246452A1 (en) 2020-08-06
AU2009259923A1 (en) 2009-12-23
WO2009155535A3 (en) 2010-04-22
JP2011525191A (ja) 2011-09-15
US12070496B2 (en) 2024-08-27
US20210000943A1 (en) 2021-01-07
JP6342982B2 (ja) 2018-06-13
US20180153982A1 (en) 2018-06-07
US20220387582A1 (en) 2022-12-08
JP2017081960A (ja) 2017-05-18
US20200345837A1 (en) 2020-11-05
CA2728739C (en) 2017-07-11
EP4218806A1 (en) 2023-08-02
US9764026B2 (en) 2017-09-19
US11351248B2 (en) 2022-06-07
AU2009259923B2 (en) 2015-09-03
DK3156069T3 (da) 2020-09-21
EP2303319B1 (en) 2016-10-05
US20210000944A1 (en) 2021-01-07
US20120288473A1 (en) 2012-11-15
US11364295B2 (en) 2022-06-21

Similar Documents

Publication Publication Date Title
US12070496B2 (en) Compositions, methods and kits for eliciting an immune response
US9950056B2 (en) Compositions, methods and kits for eliciting an immune response
Reis et al. Deletion of African swine fever virus interferon inhibitors from the genome of a virulent isolate reduces virulence in domestic pigs and induces a protective response
Jiang et al. Optimized multi-epitope neoantigen human cytomegalovirus vaccine based on adenovirus vectors elicits potent antiviral immunity
US20110236345A1 (en) Composition and methods for eliciting an immune response
Gong et al. Biological characteristics of a precocious line of Eimeria tenella
CN120966863A (zh) 一种基因敲除减毒的颗粒溶素/il-12重组质粒和重组卡介苗及应用
Manlove Anti-leukemia immunity is enabled by unmasking cross-reactive antigens with vaccination and checkpoint blockade
HK40059969A (en) Compositions, methods and kits for eliciting an immune response
Dongxiao DNA METHYLATION

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110713